Monte Rosa Therapeutics, Inc. (GLUE) Form 10-Q Quarterly Reports
Monte Rosa Therapeutics, Inc. (GLUE) is a publicly traded company on the Nasdaq, categorized under SIC 2836 (Biological Products, (No Diagnostic Substances)). Access real-time SEC filings, 10-K annual reports, 10-Q quarterlies, 8-K current reports, PCAOB auditor history, and executive compensation disclosures.
Ticker: GLUE
CIK: 1826457
Exchange: Nasdaq
SIC 2836: Biological Products, (No Diagnostic Substances)
Fiscal Year End: 12/31
State: DE
Independent PCAOB Auditor
Explore PCAOB Audit Intelligence →
Audit Firm
Deloitte & Touche LLP
Auditor SinceSince 12/31/2020 12:00:00 AM
Lead Engagement PartnerRichard Tavolieri
Audit LocationBoston, Massachusetts, United States
Latest SEC EDGAR Filings
Showing 10-K, 10-Q, 8-K, Form 4, and other SEC submissions| Form | Filing Date | Reporting Period | Description | Accession Number | Actions |
|---|---|---|---|---|---|
| 4 | 2026-10-06 | 2026-10-05 | 4 | 0001193125-26-415540 | View SEC Doc Filr Page |
| 8-K | 2026-10-01 | 2026-10-01 | 8-K | 0001193125-26-409833 | View SEC Doc Filr Page |
| 8-K | 2026-09-08 | 2026-09-08 | 8-K | 0001193125-26-384360 | View SEC Doc Filr Page |
| SCHEDULE 13G/A | 2026-08-14 | — | SCHEDULE 13G/A Filing | 0000919574-26-005533 | View SEC Doc Filr Page |
| SCHEDULE 13G | 2026-08-14 | — | SCHEDULE 13G Filing | 0000902664-26-003506 | View SEC Doc Filr Page |
| 10-Q | 2026-08-06 | 2026-06-30 | 10-Q | 0001193125-26-336711 | View SEC Doc Filr Page |
| 8-K | 2026-08-06 | 2026-08-06 | 8-K | 0001193125-26-336681 | View SEC Doc Filr Page |
| 4 | 2026-07-17 | 2026-07-16 | 4 | 0001193125-26-307791 | View SEC Doc Filr Page |
| 4 | 2026-07-16 | 2026-07-15 | 4 | 0001193125-26-306110 | View SEC Doc Filr Page |
| 144 | 2026-07-16 | — | 144 Filing | 0001950047-26-007144 | View SEC Doc Filr Page |
| 144 | 2026-07-15 | — | 144 Filing | 0001969223-26-000786 | View SEC Doc Filr Page |
| SCHEDULE 13G/A | 2026-07-08 | — | SCHEDULE 13G/A Filing | 0000080255-26-000442 | View SEC Doc Filr Page |
| 4 | 2026-07-07 | 2026-07-06 | 4 | 0001193125-26-297558 | View SEC Doc Filr Page |
| 4 | 2026-07-06 | 2026-07-01 | 4 | 0001193125-26-296490 | View SEC Doc Filr Page |
| SCHEDULE 13D/A | 2026-07-06 | — | SCHEDULE 13D/A Filing | 0001072613-26-000558 | View SEC Doc Filr Page |
| 4 | 2026-07-01 | 2026-06-30 | 4 | 0001193125-26-292767 | View SEC Doc Filr Page |
| 144 | 2026-06-30 | — | 144 Filing | 0001950047-26-006665 | View SEC Doc Filr Page |
| 4 | 2026-06-30 | 2026-06-29 | 4 | 0001193125-26-290486 | View SEC Doc Filr Page |
| 4 | 2026-06-30 | 2026-06-29 | 4 | 0001193125-26-290484 | View SEC Doc Filr Page |
| 144 | 2026-06-29 | — | 144 Filing | 0001950047-26-006612 | View SEC Doc Filr Page |
| 144 | 2026-06-29 | — | 144 Filing | 0001950047-26-006574 | View SEC Doc Filr Page |
| 4 | 2026-06-25 | 2026-06-23 | 4 | 0001193125-26-282740 | View SEC Doc Filr Page |
| 4 | 2026-06-25 | 2026-06-23 | 4 | 0001193125-26-282735 | View SEC Doc Filr Page |
| 4 | 2026-06-25 | 2026-06-23 | 4 | 0001193125-26-282736 | View SEC Doc Filr Page |
| 144 | 2026-06-24 | — | 144 Filing | 0001950047-26-006456 | View SEC Doc Filr Page |